Yes — the peer-reviewed evidence supports meaningful benefits to dermal collagen content, skin thickness, elasticity, and barrier function in appropriately-selected postmenopausal women taking menopausal hormone therapy (also called HRT or MHT).
The mechanistic case is straightforward. Estradiol supports collagen synthesis in dermal fibroblasts through estrogen receptor pathways. When endogenous estradiol declines at menopause, dermal collagen declines with it — roughly 30% in the first five years post-menopause (Brincat, 1983; Affinito, 1999). Restoring circulating estradiol through MHT partially reverses or slows that trajectory.
Verdier-Sévrain's foundational 2006 review synthesized the collagen and skin thickness evidence (Verdier-Sévrain, 2006). Stevenson and Thornton's later review specifically addressed the effect of estrogens and selective estrogen receptor modulators (SERMs) on skin aging (Stevenson & Thornton, 2007). Rzepecki's 2019 dermatology-focused review summarized the clinical implications for skin (Rzepecki, 2019).
The current authoritative clinical guidance on MHT is the North American Menopause Society 2022 Position Statement (NAMS, 2022). It's the most-cited framework for HRT decision-making today, and it supports MHT for symptom management and long-term risk reduction in appropriately-selected women — with skin benefits recognized alongside the primary indications.
What HRT is and isn't. HRT is a medical intervention with real risks and benefits that requires individualized clinical decision-making with a physician. It is not a cosmetic product. But for many women whose skin is undergoing the collagen loss driven by estradiol decline, HRT is a tool with peer-reviewed evidence.
The JenSkin panel measures estradiol as part of the standard nine. Knowing where your estradiol sits — and how it's shaping the other markers on your panel — is often the foundation for a productive conversation with your physician about whether MHT is worth exploring.